Evidence map›Paper›PMID 32333080›Full record

ArticleCancer immunology, immunotherapy : CII2020

IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18.

Naoto Oka, Tzvetanka Markova, Kenzo Tsuzuki, Wen Li, Yosif El-Darawish, Magdalena Pencheva-Demireva, Kyousuke Yamanishi, Hiromichi Yamanishi, Masafumi Sakagami, Yoshimasa Tanaka and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Safety and Feasibility of InfusingbioRxiv : the preprint server for biology · 2026
    Article
  7. IL-18-Mediated Tumor Immune Evasion.Current issues in molecular biology · 2026
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. The role of CD56Journal of neuroinflammation · 2024
    Review
  19. Molecular Mechanisms of IL18 in Disease.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Naoto OkaDepartment of Otorhinolaryngology-Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.ORCID http://orcid.org/0000-0003-4352-7606
Tzvetanka MarkovaDepartment of Pharmacology, Medical University, Sofia, Bulgaria.
Kenzo TsuzukiDepartment of Otorhinolaryngology-Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Wen LiLaboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Yosif El-DarawishDepartment of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Magdalena Pencheva-DemirevaDepartment of Biology, Medical University, Sofia, Bulgaria.
Kyousuke YamanishiDepartment of Neuropsychiatry, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Hiromichi YamanishiHirakata General Hospital for Developmental Disorders, Hirakata, Osaka, Japan.
Masafumi SakagamiDepartment of Otorhinolaryngology-Head and Neck Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Yoshimasa TanakaCenter for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Haruki OkamuraLaboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan. haruoka@hyo-med.ac.jp.
Hyogo Medical University · JPMedical University of Sofia · BGHiraka General Hospital · JPNagasaki University · JPNational Center of Neurology and Psychiatry · JP

Funding

Japan Agency for Medical Research and Development JP18nk0101355h0102Japan Society for the Promotion of Science, KAKENHI JP16K11220Japan Society for the Promotion of Science, KAKENHI JP25462671
6 · The paper itself

Abstract

NK cells, which are composed of phenotypically and functionally heterogeneous subpopulations, play critical roles in immunity against cancer. The mechanism of generation of distinct subsets such as the effector and regulatory subtypes is unclear. Here, we show that this process comprises several steps, including generation of proliferating, highly cytotoxic cells activated by IL-15/IL-18 and differentiation into distinct cell populations induced with IL-12. Freshly prepared murine splenic NK cells expressed IL-15Rs and IL-18Rs and rapidly began to proliferate following stimulation with IL-15/IL-18. The proliferating NK cells highly expressed various activation markers such as B220, CD49b (DX5), lysosome-associated membrane glycoprotein 1 (LAMP-1), DNAX accessory molecule 1, perforin, and granzyme B and showed reduced expression of natural killer cell p46-related protein (NKp46) and IL-18Rα. These cells exerted strong cytotoxicity against YAC-1 cells, but did not secrete cytokines. IL-12 rapidly activated STAT4 in these cells, induced IFN-γ production, and then upregulated p21 and p27, leading to withdrawal from the cell cycle. In parallel, IL-12-stimulated cells gradually reduced cytotoxicity, decreased expression of activation markers, and instead increased expression of Sca-1, CD25, CD49a, and NKp46. Some IL-15/IL-18-induced cells strongly expressed PD-1, whereas NK cells induced with IL-15/IL-18 and IL-12 expressed high levels of T cell immunoglobulin mucin-3, LAG-3, and natural killer group 2 A. Furthermore, these cells spontaneously secreted IL-10 and TGF-β following prolonged incubation. Thus, IL-12 regulates expansion of NK cells activated with IL-15/IL-18, influences the population size of highly cytotoxic cells, and induces differentiation to unique cells sharing some phenotypes of ILCs.

Indexed as

AnimalsCell LineCell ProliferationCytotoxicity, ImmunologicInterleukin-12Interleukin-15Interleukin-18Killer Cells, NaturalMaleMiceMice, KnockoutPhenotypeSignal TransductionT-LymphocytesInterleukin-12Interleukin-15Interleukin-18Cancer immunotherapyCytokinesInnate lymphoid cellsNK cell differentiationNK cell proliferation

Identifiers

PMID32333080
PMCPMC11027610
OpenAlexW3020535503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.